公开(公告)号：US20220402964A1

公开(公告)日：2022-12-22

申请号：US17883398

申请日：2022-08-08

申请人： Graybug Vision, Inc.

发明人： Hans-Gottfried Genieser ,  Frank SCHWEDE ,  Andreas RENTSCH ,  Per EKSTRÖM ,  Valeria MARIGO ,  Francois PAQUET-DURAND

IPC分类号： C07H21/00 ,  A61P27/02 ,  C07H19/213 ,  C07H19/23

摘要： Embodiments of the invention are directed to new equatorially modified polymer linked multimers of guanosine-3′, 5′-cyclic monophosphate (cGMP) analogues that inhibit the cGMP-signaling system. The invention is also directed to related monomeric compounds, which may serve as monomeric precursors of the multimers, and/or also show itself inhibitory activity and/or impact the inhibitory activity of the related multimers. The invention further relates to the use of such compounds as reagents for signal transduction research and as modulators of cyclic nucleotide-regulated binding proteins and isoenzymes thereof, and as ligands for affinity chromatography, for antibody production or for diagnostic applications, e.g., on chip surfaces.

公开(公告)号：US11339185B2

公开(公告)日：2022-05-24

申请号：US16683667

申请日：2019-11-14

申请人： Bristol-Myers Squibb Company

发明人： Brian E. Fink ,  Dharmpal S. Dodd ,  Steven J. Walker ,  Libing Chen ,  Yufen Zhao ,  Zheming Ruan ,  Lan-Ying Qin ,  Peter Kinam Park ,  Muthoni G. Kamau ,  Lalgudi S. Harikrishnan

IPC分类号： C07H19/213 ,  A61P35/00 ,  C07H21/02 ,  C07H21/00 ,  C07K16/28

摘要： The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

公开(公告)号：US11192914B2

公开(公告)日：2021-12-07

申请号：US16097382

申请日：2017-04-28

申请人： Emory University

发明人： Gregory Bluemling ,  Abel De La Rosa ,  George Painter ,  Damien Kuiper ,  Alexander Kolykhalov

IPC分类号： C07H19/06 ,  A61K45/06 ,  C07H19/10 ,  C07H19/12 ,  C07H19/14 ,  C07H19/20 ,  C07H19/11 ,  C07H19/213 ,  A61P31/14 ,  A61K31/706 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/7076 ,  C07H19/16

摘要： This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the nucleotide or nucleoside is defined by Formula I below,

公开(公告)号：US20210340169A1

公开(公告)日：2021-11-04

申请号：US17284154

申请日：2019-10-12

申请人： SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD. ,  JIANGXI JEMINCARE GROUP CO., LTD.

发明人： Shuchun GUO ,  Jianbiao PENG ,  Yang LIU ,  Haibing GUO

IPC分类号： C07H19/213 ,  A61P35/00

摘要： Provided are a compound of formula (I), an optical isomer thereof, a pharmaceutically acceptable salt thereof, uses of said compound acting as a STING agonist.

公开(公告)号：US10913766B2

公开(公告)日：2021-02-09

申请号：US16907213

申请日：2020-06-20

申请人： ZHEJIANG PALO ALTO PHARMACEUTICALS, INC.

发明人： Zhijian Xi ,  Huaqiang Xu ,  Chunping Lu ,  Zhongshan Wu

IPC分类号： C07H19/213 ,  C07F9/6571 ,  C07D473/18 ,  C07H19/11 ,  A61P1/16

摘要： Disclosed is a liver specific delivery (LSD)-based entecavir antiviral prodrug, i.e., a nucleoside cyclic phosphate compound, and the application thereof. Specifically, disclosed are a compound as represented by formula (I) and isomers, pharmaceutically acceptable salts, hydrates, and solvates of the compound, and a corresponding pharmaceutical composition. Also disclosed is the application of the compound of the present invention, used separately or used in combination with other antiviral drugs, against viruses, especially the application against hepatitis B virus (HBV).

公开(公告)号：US10342882B2

公开(公告)日：2019-07-09

申请号：US15265158

申请日：2016-09-14

申请人： The Regents of the University of California ,  The Research Foundation for The State University of New York

发明人： Jose Manuel Mejia Oneto ,  Maksim Royzen

IPC分类号： A61K51/06 ,  A61K38/14 ,  C07D257/08 ,  A61K49/00 ,  A61K51/04 ,  C07D311/82 ,  C07D499/74 ,  C07H7/02 ,  C07H15/24 ,  C07H19/167 ,  C07H19/213 ,  A61K31/43 ,  A61K31/7076 ,  A61K38/12 ,  A61K51/12 ,  A61K47/54 ,  A61K47/61 ,  A61K47/66 ,  A61K47/69

摘要： The present invention provides a method for selective delivery of a therapeutic or diagnostic agent to a targeted organ or tissue by implanting a biocompatible solid support in the patient being linked to a first binding agent, and administering a second binding agent to the patient linked to the therapeutic or diagnostic agent, such that the therapeutic or diagnostic agent accumulates at the targeted organ or tissue.

公开(公告)号：US20190177357A1

公开(公告)日：2019-06-13

申请号：US16182302

申请日：2018-11-06

申请人： WAVE LIFE SCIENCES LTD.

发明人： Mamoru Shimizu ,  Takeshi Wada

IPC分类号： C07H23/00 ,  C07H19/207 ,  C07H19/10 ,  C07H1/00 ,  C07F7/08 ,  C07D473/34 ,  C07B53/00 ,  C07D405/04 ,  C07D207/08 ,  C07H21/04 ,  C07H19/213 ,  C07H19/11 ,  C07D473/18

摘要： To provide a chiral reagent or a salt thereof.The chiral reagent has following chemical formula (I). In the formula (I), G1 and G2 are independently a hydrogen atom, a nitro group (—NO2), a halogen atom, a cyano group (—CN), a group of formula (II) or (III), or both G1 and G2 taken together to form a group of formula (IV).

公开(公告)号：US10092649B2

公开(公告)日：2018-10-09

申请号：US15187014

申请日：2016-06-20

申请人： Riboscience LLC

发明人： Mark Smith ,  Klaus G. Klumpp

IPC分类号： C07H7/06 ,  A61K45/06 ,  C07H19/06 ,  C07H19/10 ,  A61K31/7068 ,  C07H19/16 ,  A61K31/7076 ,  A61K31/708 ,  C07H19/213 ,  A61K31/7072

摘要： The application discloses nucleoside derivatives of Formula I as inhibitors of Influenza RNA replication. In particular, the application discloses the use of purine and pyrimidine nucleoside derivatives of Formula I as inhibitors of Influenza RNA replication and pharmaceutical compositions containing such compounds.

公开(公告)号：US09862743B2

公开(公告)日：2018-01-09

申请号：US14510451

申请日：2014-10-09

申请人： Alios BioPharma, Inc.

发明人： Leonid Beigelman ,  Guangyi Wang ,  David Bernard Smith ,  Marija Prhavc ,  Christian Andreas Jekle ,  Jerome Deval

IPC分类号： A61K31/7052 ,  A61K31/7064 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  C07H19/20 ,  C07H19/06 ,  C07H19/16 ,  C07H19/10 ,  C07H19/11 ,  C07H19/207 ,  C07H19/213

CPC分类号： C07H19/20 ,  A61K31/7052 ,  A61K31/7064 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  C07H19/06 ,  C07H19/10 ,  C07H19/11 ,  C07H19/16 ,  C07H19/207 ,  C07H19/213

摘要： Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Picornavirus and/or Flaviviridae infection with one or more nucleosides, nucleotides and nucleotide analogs.

公开(公告)号：US20170296664A1

公开(公告)日：2017-10-19

申请号：US15187014

申请日：2016-06-20

申请人： Riboscience LLC

发明人： Mark Smith ,  Klaus G. Klumpp

IPC分类号： A61K45/06 ,  C07H19/16 ,  C07H19/10 ,  C07H19/06 ,  A61K31/708 ,  A61K31/7076 ,  A61K31/7072 ,  C07H19/213 ,  A61K31/7068

CPC分类号： A61K45/06 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  C07H7/06 ,  C07H19/06 ,  C07H19/10 ,  C07H19/16 ,  C07H19/213 ,  A61K2300/00

摘要： The application discloses nucleoside derivatives of Formula I as inhibitors of Influenza RNA replication. In particular, the application discloses the use of purine and pyrimidine nucleoside derivatives of Formula I as inhibitors of Influenza RNA replication and pharmaceutical compositions containing such compounds.